IMNM
Immunome, Inc. · Healthcare · Biotechnology
Last
$21.88
−$0.02 (−0.07%) 4:00 PM ET
After hours $21.85 −$0.02 (−0.11%) 6:09 PM ET
Prev close $21.89
Open $21.31
Day high $22.13
Day low $21.31
Volume 1,005,698
Avg vol 1,446,983
Mkt cap
$2.41B
P/E ratio
-7.42
FY Revenue
$9.68M
EPS
-2.95
Gross Margin
-1,473.96%
Sector
Healthcare
AI report sections
IMNM
Immunome, Inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
+25% (Above avg)
Vol/Avg: 1.25×
RSI
43.45 (Neutral)
Neutral (40–60)
MACD momentum
Intraday
+0.03 (Strong)
MACD: 0.07 Signal: 0.05
Short-Term
-0.31 (Weak)
MACD: -0.38 Signal: -0.07
Long-Term
-0.37 (Weak)
MACD: 0.44 Signal: 0.81
Intraday trend score 34.00

Latest news

IMNM 12 articles Positive: 0 Neutral: 0 Negative: 0
Unknown Benzinga • Benzinga Insights
Evaluating Immunome: Insights From 4 Financial Analysts

In the preceding three months, 4 analysts have released ratings for Immunome (NASDAQ:IMNM), presenting a wide array of perspectives from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 2 0 0 0 3M Ago 0 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.75, a high estimate of $35.00, and a low estimate of $24.00. This current average reflects an increase of 10.19% from the previous average price target of $27.00. Understanding Analyst Ratings: A Comprehensive Breakdown A comprehensive examination of how financial experts perceive Immunome is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Biren Amin Piper Sandler Announces Overweight $27.00 - Brian Cheng JP Morgan Announces Overweight $24.00 - Michael Schmidt Guggenheim Announces Buy $35.00 - David Nierengarten Wedbush Raises Outperform $33.00 $27.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Immunome. This offers insight ...Full story available on Benzinga.com

IMNM Analyst Ratings
Unknown Zacks Investment Research • Zacks Equity Research
Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates

Immunome (IMNM) delivered earnings and revenue surprises of 57.50% and 74.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

IMNM AQB
Unknown Zacks Investment Research • Zacks Equity Research
Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for

Immunome (IMNM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IMNM EXEL
Unknown Zacks Investment Research • Zacks Equity Research
New Strong Sell Stocks for April 4th

IMNM, SLOIF and TMQ have been added to the Zacks Rank #5 (Strong Sell) List on April 4, 2023.

SLOIF TMQ IMNM
Unknown Zacks Investment Research • Zacks Equity Research
Company News for Apr 2, 2024

Companies In The News Are: SMTC, OXM, IMNM, GOOGL.

SMTC OXM GOOGL IMNM
Unknown Benzinga • Piero Cingari
Stocks Pause As Traders Reassess Interest Rate Path, Gold Makes New Highs, Bitcoin Rebounds: What's Driving Markets Thursday?

In the final session of the short trading week leading up to Easter festivities, U.S. equity indices held steady, reflecting some setbacks in market expectations regarding interest rate reductions. On Wednesday, Fed Governor Christopher J. Waller spoke in opposition to an early interest rate cut, citing the still uncertain inflation path, and noted that his stance is shared by a robust share of the Fed board. Thursday saw an upward revision to the fourth-quarter U.S. gross domestic product, with the economy expanding by 3.4% on an annualized basis, exceeding the previously estimated 3.2%. Traders marginally scaled back their bets on a June rate cut scenario, now placing the likelihood at 64%, down from 70% on Wednesday, according to the CME Group’s FedWatch tool. While the S&P 500 and the Dow remained unchanged for the day, the Nasdaq 100 eased by 0.2%, influenced by reduced rate cut expectations and increasing commodity prices that weighed on tech companies. Gold surged to $2,225 per ounce intraday ...Full story available on Benzinga.com

QQQ REX DIA RH Analyst Color Equities Cryptocurrency Large Cap
Unknown Benzinga • Avi Kapoor
Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday

U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday. Shares of Worthington Steel, Inc. (NYSE: WS) rose sharply during Friday’s session as the company posted stronger-than-expected results for its third quarter. Worthington Steel posted adjusted earnings of 99 cents per share, beating market estimates of 84 cents per share. The company’s quarterly sales came in at $805.80 million, versus expectations of $700.50 million, according to data from Benzinga Pro. Worthington Steel shares jumped 18.8% to $37.92 on Friday. Here are some other big stocks recording gains in today’s session. Murano Global Investments PLC (NASDAQ: MRNO) shares gained 147.5% to $23.94 after falling 46% on ...

DNTH LAAC ALAB DAVE News Penny Stocks Small Cap Intraday Update
Unknown Benzinga • Erica Kollmann
Biotech Stocks Surge To Start 2024: 'Charts Look Great,' But Will The Trend Continue?

The biotech sector has been surging in recent months, reawakening from a period of underperformance that followed the 2021 highs. David Prince, professional trader at T3 Trading Group, joined Benzinga's “PreMarket Prep” on Tuesday and discussed the biotech industry, highlighting Viking Therapeutics, Inc. (NASDAQ:VKTX) and Immunome, Inc. (NASDAQ:IMNM) as notable recent movers. "I look for wherever I can make the most amount of money, legally, with the least amount of risk. Biotech into ‘24 was definitely one of those areas," Prince said.  What To Know: Prince believes large biotech companies are looking to recapture growth while sitting on large amounts of capital. The professional trader expects these companies to find new growth opportunities through mergers, acquisitions and purchasing assets as ...Full story available on Benzinga.com

XBI VKTX IMNM News Biotech Movers ETFs
Unknown Zacks Investment Research • Zacks Equity Research
Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up

Immunome (IMNM) inks an asset purchase agreement with Ayala Pharmaceuticals to acquire the latter's investigational candidate, AL102, being developed for treating desmoid tumors. Stock rises.

PBYI SWTX IMNM IMCR
Unknown Zacks Investment Research • Zacks Equity Research
Immunome (IMNM) Surges on Merger Agreement With Morphimmune

Immunome's (IMNM) shares rise following its announcement to merge with Morphimmune. The synergy will help strengthen the development of oncology therapies.

NVS AKRO IMNM OMGA
Unknown Benzinga • Lisa Levin
Nasdaq Moves Lower; Acuity Brands Earnings Top Estimates

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 200 points on Thursday. The Dow traded up 0.68% to 34,081.83 while the NASDAQ fell 0.23% to 13,560.57. The S&P 500, also rose, gaining, 0.28% to 4,389.22. Check This Out: Check Out 3 High-Yielding Dividend Stocks In Materials Sector From Wall Street's Most Accurate Analysts   Leading and Lagging Sectors Financials shares jumped by 1.5% on Thursday. In trading on Thursday, communication services shares fell by 0.6%.   Top Headline Acuity Brands, Inc (NYSE: AYI) reported better-than-expected earnings for its third quarter on Thursday. Acuity Brands reported a third-quarter FY23 net sales decline of 5.7% year-over-year to $1.0 billion, missing the consensus of $1.05 billion. Adjusted EPS of $3.75 beat the consensus of $3.71.   Equities Trading UP Sigilon Therapeutics, Inc. (NASDAQ: SGTX) shares shot up 505% to $23.67 after Eli Lilly agreed to acquire the company for $14.92/share in cash. Shares of Eco Wave Power Global AB (NASDAQ: WAVE) got a boost, shooting 23% to $1.9206 after the company announced plans for a share repurchase program of up to 10% of the total number of shares in the company. Immunome, Inc. (NASDAQ: IMNM) shares were also up, gaining 34% to $7.90 after the company and Morphimmune announced a definitive merger agreement and simultaneous private placement investment ...

WAVE AYI MOBQ BTAI News Earnings Penny Stocks Eurozone
Unknown Benzinga • Lisa Levin
Why Franklin Covey Shares Are Trading Higher By 25%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Gainers Sigilon Therapeutics, Inc. (NASDAQ: SGTX) shares climbed 523.8% to $24.25 after Eli Lilly agreed to acquire the company for $14.92/share in cash. Eco Wave Power Global AB (NASDAQ: WAVE) gained 47.4% to $2.30. Eco Wave Power Global announced plans for share repurchase program of up to 10% of total number of shares in the company. Immunome, Inc. (NASDAQ: IMNM) shares climbed 37% to $8.10. Immunome and Morphimmune reported definitive merger agreement and simultaneous private placement investment of $125 million to develop targeted cancer therapies. TOP Financial Group Limited (NASDAQ: TOP) gained 34.5% to $7.60. Franklin Covey Co. (NYSE: FC) gained 25.2% to $44.72 following upbeat third-quarter results. Carriage Services, Inc. (NYSE: CSV) surged 24.4% to $34.89 after its Board of Directors initiated a process to explore potential strategic alternatives. The Greenbrier Companies, Inc. (NYSE: GBX) gained 23.2% to $40.00 after the company reported better-than-expected third-quarter adjusted EPS and sales results and raised FY23 revenue guidance above estimates. RenovoRx, Inc. (NASDAQ: RNXT) rose 22.7% to $2.75 after the company released interim data on progression-free survival from Phase 3 study of RenovoGem for pancreatic cancer. Fangdd Network Group Ltd. (NASDAQ: DUO) shares climbed 20.7% to $0.9299 after dropping 11% on Wednesday. FangDD Network Group recently received Nasdaq notice regarding minimum bid price requirements. FREYR Battery (NYSE: FREY) gained 20.2% to $9.07 after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and announced a $13 price target. Kubient, Inc. (NASDAQ: KBNT) surged 19.5% to $0.5499. Wallbox N.V. (NYSE: WBX) gained 18% to $3.48. Wallbox 13D filing showed Orilla Asset Management, S.L. increased stake in the company to 9.1%. Shapeways Holdings, Inc. (NYSE: SHPW) gained 17.5% to $3.47 after the company announced securing two new Tier 1 supplier contracts. ZIVO Bioscience, Inc. (NASDAQ: ZIVO) rose 17% to $2.7483 after declining over 3% on Wednesday. Amyris, Inc. (NASDAQ: AMRS) climbed 16.3% ...

HY SRGA ISPR MOBQ News Penny Stocks Small Cap Intraday Update
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal